Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca
The outlay, which is backed by up to 1.4 billion euros in milestones, strengthens Merck’s hand in a cancer field targeted by AstraZeneca and Gilead.
Nick Paul Taylor
Oct 30, 2023 8:40am
Merck KGaA's MS drug passes durability test ahead of ph. 3 data
Oct 11, 2023 9:49am
Madrigal COO departs days after new CEO starts—Chutes & Ladders
Sep 29, 2023 9:30am
Merck KGaA grows Quris toxicity AI pact, continuing deal flurry
Sep 28, 2023 10:10am
Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery
Sep 20, 2023 6:00am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
